(Q42927772)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23569320%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

editorial

0 references

title

Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23569320%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

main subject

phase III clinical trial

0 references

1 reference

Emmanuel S Antonarakis

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23569320%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Mario A Eisenberger

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23569320%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

8 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23569320%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Oncology

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23569320%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23569320%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23569320%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

1709-1712

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23569320%20AND%20SRC:MED&resulttype=core&format=json

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

28 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4812821

Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4812821

End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4812821

Expanding treatment options for metastatic prostate cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4812821

Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4812821

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4812821

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4812821

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4812821

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4812821

A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4812821

Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23569320

12 December 2020

inferred from PubMed ID database lookup

Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23569320

12 December 2020

inferred from PubMed ID database lookup

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23569320

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1200/JCO.2013.48.8825

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23569320%20AND%20SRC:MED&resulttype=core&format=json

release_2fojftfmn5ckbdtfbf25dgpnlq

28 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/2fojftfmn5ckbdtfbf25dgpnlq

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23569320%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference